Skip to main content

TG Therapeutics, Inc.

TGTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001001316

In the last 90 days, TG Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 431 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; no superinvestor holds it.

13F holders, Q2 2022

Institutional positions in TG Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
175
−2 vs. Q1 2022
Shares held
106.4M
+5.56M (+5.5%) vs. Q1 2022
Total value
$452.6M
−$505.9M (−52.8%) vs. Q1 2022
New holders
28
68 more added
Sold out
30
54 more reduced

4 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting TGTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2022: 175 institutions
Q1 2021: 240 institutionsQ2 2021: 237 institutionsQ3 2021: 223 institutionsQ4 2021: 194 institutionsQ1 2022: 181 institutionsQ2 2022: 175 institutionsQ3 2022: 183 institutionsQ4 2022: 198 institutionsQ1 2023: 214 institutionsQ2 2023: 244 institutionsQ3 2023: 236 institutionsQ4 2023: 236 institutionsQ1 2024: 241 institutionsQ2 2024: 259 institutionsQ3 2024: 308 institutionsQ4 2024: 331 institutionsQ1 2025: 376 institutionsQ2 2025: 356 institutionsQ3 2025: 354 institutionsQ4 2025: 352 institutionsQ1 2026: 365 institutionsQ2 2026: 431 institutions
Value heldQ2 2022: $452.6M
Q1 2021: $4.77BQ2 2021: $3.73BQ3 2021: $3.21BQ4 2021: $1.90BQ1 2022: $960.0MQ2 2022: $452.6MQ3 2022: $594.6MQ4 2022: $1.11BQ1 2023: $1.43BQ2 2023: $2.19BQ3 2023: $756.4MQ4 2023: $1.55BQ1 2024: $1.38BQ2 2024: $1.66BQ3 2024: $2.38BQ4 2024: $2.92BQ1 2025: $3.90BQ2 2025: $3.65BQ3 2025: $3.58BQ4 2025: $3.07BQ1 2026: $3.50BQ2 2026: $6.10B
Institutions holding TGTX and their total value by quarter
QuarterHoldersValue
Q2 2026431$6.10B
Q1 2026365$3.50B
Q4 2025352$3.07B
Q3 2025354$3.58B
Q2 2025356$3.65B
Q1 2025376$3.90B
Q4 2024331$2.92B
Q3 2024308$2.38B
Q2 2024259$1.66B
Q1 2024241$1.38B
Q4 2023236$1.55B
Q3 2023236$756.4M
Q2 2023244$2.19B
Q1 2023214$1.43B
Q4 2022198$1.11B
Q3 2022183$594.6M
Q2 2022175$452.6M
Q1 2022181$960.0M
Q4 2021194$1.90B
Q3 2021223$3.21B
Q2 2021237$3.73B
Q1 2021240$4.77B

Institutions, Q2 2022

Shares, value and share of portfolio for each institution holding TG Therapeutics, Inc.; share changes are against Q1 2022.

Institutions holding TGTX in Q2 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Evoke Wealth, LLC0$00.00%−219−100.0%Sold out
Money Concepts Capital Corp0$00.00%−151−100.0%Sold out
Glassman Wealth Services0$00.00%−77−100.0%Sold out
Central Trust Co0$00.00%−16−100.0%Sold out
Capital Advisors, Ltd. LLC0$00.00%−17−100.0%Sold out
Parametric Portfolio Associates LLC––––Not filed
Amalgamated Financial Corp.––––Not filed
Clark Financial Services Group Inc––––Not filed
Virginia Retirement Systems Et Al––––Not filed